About Dr. Fei Jian
Dr. Fei Jian (费健) is a Chief Physician (主任医师) in the Department of General Surgery at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine. Widely respected among patients and peers for his expertise in thyroid cancer and thyroid nodule management, Dr. Fei practices within one of China's top-ranked general surgery departments — a program that consistently places among the national leaders in surgical volume, academic output, and clinical outcomes.
Dr. Fei has built a strong clinical reputation through years of focused practice in thyroid surgery, earning the trust of patients who seek him out specifically for his careful, patient-centered approach to thyroid cancer diagnosis and surgical decision-making. His expertise spans the full spectrum of thyroid disease — from the evaluation and surveillance of benign nodules to the surgical management of complex thyroid malignancies — making him a comprehensive resource for international patients navigating thyroid health concerns.
Clinical Expertise
- Thyroid cancer surgery — total thyroidectomy and hemithyroidectomy for papillary, follicular, and medullary thyroid carcinoma; central and lateral neck dissection for lymph node metastases; management of locally advanced thyroid cancer
- Thyroid nodule evaluation and management — risk stratification using ultrasound (ACR TI-RADS, C-TIRADS), fine needle aspiration (FNA) cytology interpretation, and evidence-based surgical decision-making for indeterminate nodules
- Minimally invasive thyroid surgery — endoscopic and robotic-assisted approaches for eligible patients seeking scarless surgery
- Recurrent laryngeal nerve preservation — intraoperative nerve monitoring (IONM) to protect voice function during thyroid surgery
- Parathyroid preservation — identification and preservation of parathyroid glands during thyroidectomy to minimize postoperative hypocalcemia
- Active surveillance for low-risk thyroid cancer — evidence-based monitoring protocols for patients with very low-risk papillary microcarcinomas who prefer to defer surgery
- Multidisciplinary treatment coordination — integration of surgery with radioactive iodine therapy, TSH suppression, and targeted therapy for advanced or recurrent thyroid cancer
Why Dr. Fei Jian?
Dr. Fei's strong patient reputation reflects a clinical approach that combines technical surgical skill with careful, individualized counseling — qualities that are particularly important in thyroid cancer, where the range of appropriate management options (from active surveillance to total thyroidectomy with neck dissection) is wide, and where patients benefit from a surgeon who takes the time to explain the evidence and align treatment with their personal circumstances and preferences.
For international patients who may have received conflicting advice about whether and how to treat their thyroid cancer or nodule, Dr. Fei's experience at Ruijin Hospital — one of China's top general surgery programs — provides a credible, evidence-based second opinion grounded in both Chinese and international guidelines (ATA, NCCN, Chinese Thyroid Association).
Ruijin Hospital's general surgery department is consistently ranked among the top programs in China, with a high annual surgical volume that translates directly into surgical expertise and low complication rates. The hospital's endocrinology department — one of the strongest in China — provides close collaboration for the medical management of thyroid conditions before and after surgery.
Hospital: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Ruijin Hospital is one of China's most prestigious academic medical centers, with a history spanning over 110 years. Affiliated with Shanghai Jiao Tong University School of Medicine, it is consistently ranked among the top hospitals in China and is internationally recognized for its endocrinology, hematology, and general surgery programs. The Department of General Surgery is a national leader in surgical volume and academic output, with subspecialty expertise across thyroid, hepatobiliary, colorectal, and bariatric surgery. The hospital's multidisciplinary tumor board ensures that complex thyroid cancer cases receive coordinated input from surgery, endocrinology, nuclear medicine, and oncology.
About Thyroid Nodules & Thyroid Cancer
Thyroid nodules are extremely common — detectable by ultrasound in up to 68% of the general population — but the vast majority are benign. The challenge lies in accurately identifying the small proportion that are malignant and require treatment. Key facts for international patients:
- Thyroid nodule evaluation: ultrasound is the primary tool; ACR TI-RADS and C-TIRADS scoring systems guide the decision to perform FNA biopsy based on nodule size and suspicious features
- FNA cytology: classified using the Bethesda System (I–VI); Bethesda III (atypia of undetermined significance) and IV (follicular neoplasm) are indeterminate categories where molecular testing (ThyroSeq, Afirma) can help guide surgical decisions
- Papillary thyroid microcarcinoma (≤1 cm): active surveillance is an internationally accepted alternative to immediate surgery for low-risk cases; 10-year progression rates are <5% in carefully selected patients
- Surgical extent: hemithyroidectomy is preferred for low-risk unifocal tumors ≤1 cm; total thyroidectomy is indicated for tumors >4 cm, bilateral disease, extrathyroidal extension, or high-risk features
- Lymph node dissection: prophylactic central neck dissection is controversial for low-risk papillary thyroid cancer; therapeutic dissection is performed for clinically involved nodes
- Radioactive iodine (RAI): not routinely recommended for low-risk differentiated thyroid cancer; indicated for intermediate/high-risk disease and distant metastases
- Targeted therapy: lenvatinib and sorafenib for RAI-refractory differentiated thyroid cancer; selpercatinib for RET-mutated disease; dabrafenib + trametinib for BRAF V600E-mutated anaplastic thyroid cancer
What to Prepare Before Your Consultation
To enable Dr. Fei's team to conduct a thorough remote case review, international patients should prepare:
- Neck ultrasound report with TI-RADS scoring and measurements of all nodules and lymph nodes
- FNA cytology report (Bethesda classification) if biopsy has been performed
- Molecular testing results if available (ThyroSeq, Afirma, or equivalent)
- CT scan of the neck and chest with contrast (for locally advanced or metastatic disease)
- Thyroid function tests: TSH, free T4, free T3
- Tumor markers: thyroglobulin (Tg) and anti-Tg antibodies; calcitonin and CEA for medullary thyroid cancer
- Genetic testing results if available (RET, BRAF, RAS mutations)
- Prior surgical or treatment records if previously operated or treated with RAI
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) coordinates access to Dr. Fei Jian and the Ruijin Hospital general surgery team for international patients. Our services include:
- Remote case review and pre-consultation assessment before you travel
- Priority appointment scheduling with Dr. Fei's team at Ruijin Hospital
- Full translation of ultrasound reports, pathology, and treatment plans
- In-hospital accompaniment by a dedicated English-speaking case manager
- Accommodation, airport transfer, and logistics coordination in Shanghai
- Post-discharge follow-up and remote consultation support after returning home
Contact us to begin your case review:
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
댓글 0개